Articles

Poll

Podcasts

Slideshows

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Results of the PREVENT CLOT study indicate use of aspirin was as effective as low-molecular-weight heparin for reducing incidence of mortality in patients hospitalized with a traumatic fracture. 

Aspirin Deemed as Effective as Heparin in Patients Hospitalized with Traumatic Fractures

A reduction in aspirin use was associated with significantly less bleeding and health care use, without an increase in thrombotic outcomes.



Reducing Aspirin Use Improves Outcomes in Patients with AF, VTE Receiving Warfarin

A recent study indicated no evident VTE risk in patients with eczema, despite FDA black box warnings for the drug class.

No Clear Risk for VTE in Eczema Patients Receiving JAK Inhibitors

New findings suggest low-dose rivaroxaban plus aspirin was associated
with lower VTE risk compared with aspirin alone. 

Continuous VTE Risk Observed After Lower Extremity Revascularization in Patients with PAD

The prevalence rate of VTE was 2% among a large population of SCD  patients  in Nigeria. 

Low Prevelance of VTE Observed Among Cohort with Sickle Cell Disease

Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively

Multiple Risk Factors Increase Risk for VTE After Surgery for IBD 

In a population aged 70 years and older, a remote history of VT was associated with an increased risk of VT independent of other factors. 

Remote History of Venous Thrombosis Associated with Risk at Older Age 

Apixaban prescription beyond 90 days showed no difference in hospitalization risk for major bleeding. 




Extended Apixaban Treatment Associated With Lower VTE Hospitalization Rate  

Investigators noted that clinically relevant risks could not be excluded with certainty despite not seeing a statistically significant increase in corresponding risks for more rare and severe thrombotic outcomes.

Oxford–AstraZeneca COVID-19 Vaccine Associated with Small Excess Risk of Deep Venous Thrombosis

A recent study showed anticoagulant therapy for 6 weeks compared to 3 months met noninferiority criteria, based on a combination of recurrent VTE risk and bleeding risk.


Reduced Anticoagulant Duration for VTE Noninferior in Patients Younger Than 21 Years 

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Venous Thromboembolism